The use of sumatriptan in the treatment of obsessive-compulsive disorder in an adolescent

Journal of Child and Adolescent Psychopharmacology

Volumn 13, Issue SUPPL. 1, 2003, Pages

  Pathak, Sanjeev ^a,b   Cottingham, Elizabeth M ^a   McConville, Brian J ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; PAROXETINE; RISPERIDONE; SUMATRIPTAN;

ADOLESCENT; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; HUMAN; LETTER; MALE; OBSESSIVE COMPULSIVE DISORDER; TREATMENT OUTCOME;

EID: 0038637262     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454603322126395     Document Type: Letter

References (4)

1. 1D receptors and obsessive-compulsive disorder. Eur Neuropsychopharmacol 11(2):169-172, 2001.
2. March JS, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook EH, Cutler NR, Dominguez R, Ferguson J, Muller B, Riesenberg R, Rosenthal M, Sallee FR, Wagner KD, Steiner H: Sertraline in children and adolescents with obsessive-compulsive disorder: A multicenter randomized controlled trial. JAMA 280(20):1752-1756, 1998.
3. 1Dβ receptor gene implicated in the pathogenesis of obsessive-compulsive disorder? Am J Psychiatry 157:1160-1161, 2000.
4. Stern L, Zohar J, Cohen R, Sasson Y: Treatment of severe, drug resistant obsessive compulsive disorder with the 5HT1D agonist sumatriptan. Eur Neuropsychopharmacol 8(4):325-328, 1998.